Pfizer $PFE (+1.01%) has discontinued the development of its oral weight loss pill Danuglipron. The reason: patients in clinical trials suffered from side effects such as nausea and vomiting. Although the drug was originally seen as a potential competitor to Wegovy and Ozempic, Pfizer no longer sees any commercial potential due to its poor tolerability. Instead, the company intends to concentrate on other active ingredients for weight reduction, such as GLP-1-based therapies. The decision marks a setback in Pfizer's strategy to gain a stronger foothold in the booming market for obesity drugs.
The news is based on what I personally consider to be reputable sources. No investment advice. Follow me for more updates!
